Search News
| 24.83 Delayed Data As of 4:01pm ET |  +0.19 / +0.77%Today’s Change | 10.85 Today|||52-Week Range 25.96 | +31.03% Year-to-Date |
| AstraZeneca's Fasenra Long-Term Asthma Study Data Positive Sep 19 / Zacks.com - Paid Partner Content | Allergan Frown Lines Study Passes Test on Higher Botox Dose Sep 17 / Zacks.com - Paid Partner Content |
| Regeneron Gains on Eylea, Dupixent and Pipeline Progress Sep 18 / Zacks.com - Paid Partner Content | Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis Sep 17 / Zacks.com - Paid Partner Content |
| Does Ajovy's Approval Make Teva a Pain-Free Stock to Buy? Sep 18 / MotleyFool.com - Paid Partner Content | Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija Sep 14 / Zacks.com - Paid Partner Content |
| New Marijuana Stocks? & Earnings from ORCL and FDX | Free Lunch Sep 17 / Zacks.com - Paid Partner Content | The SEC Takes Aim at Opko Health's Phillip Frost Sep 13 / MotleyFool.com - Paid Partner Content |
| Teva's (TEVA) Migraine Drug Ajovy Receives FDA Approval Sep 17 / Zacks.com - Paid Partner Content | AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia Sep 12 / Zacks.com - Paid Partner Content |
| Previous close | 24.64 |
| Today’s open | 24.61 |
| Day’s range | 24.52 - 25.00 |
| Volume | 9,173,315 |
| Average volume (3 months) | 11,344,823 |
| Market cap | $25.1B |
| Earnings growth (last year) | -23,426.50% |
| Earnings growth (this year) | -30.37% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | +2.60% |
| P/E ratio | NM |
| Price/Sales | 0.85 |
| Price/Book | 1.83 |
| Next reporting date | November 1, 2018 |
| EPS forecast (this quarter) | $0.55 |
| Annual revenue (last year) | $22.5B |
| Annual profit (last year) | -$16.4B |
| Net profit margin | -72.66% |
Sector Health Technology |
Industry Pharmaceuticals: Generic |
President, Chief Executive Officer & Director Kåre Schultz |
Executive Vice President- Global Operations Carlo de Notaristefani |
Corporate headquarters Petach Tikva, Hamerkaz |
